历史大底来了？2000亿医疗巨头，董事长总经理等集体出手大买，外资机构调研超400次

Core Viewpoint - The recent stock purchases by the executives of Mindray Medical, including the chairman and other senior management, indicate strong confidence in the company's future growth and intrinsic value, especially after a challenging period in the domestic market [1][8]. Group 1: Executive Stock Purchases - Chairman Li Xiting has invested approximately 29.99 million yuan by purchasing 152,300 shares at an average price of 196.862 yuan per share, marking his first stock buy [4][5]. - Li Xiting plans to continue purchasing shares in the secondary market, with a total investment expected to reach 200 million yuan over the next six months [6]. - Other executives, including General Manager Wu Hao and Senior Vice President Li Zaiwen, have also made significant stock purchases, indicating a collective belief in the company's potential [8]. Group 2: Foreign Institutional Interest - Mindray Medical has attracted significant attention from foreign institutional investors, ranking second in the number of investigations among A-share listed companies, with 404 inquiries as of December 3 [10][11]. - The interest from foreign institutions reflects their confidence in Mindray's ability to navigate market challenges and capitalize on growth opportunities [12]. Group 3: Financial Performance and Market Outlook - In Q3 2025, Mindray Medical's revenue showed a positive turnaround with a year-on-year growth of 1.53%, reversing a previous decline of 23.77% in Q2 [12][15]. - The company anticipates that the most challenging period in the domestic market has passed, with expectations for domestic business to return to positive growth next year and profit growth to turn positive by 2026 [15][20]. - Mindray's international market potential is estimated to be 4-5 times larger than the domestic market, positioning the company for long-term growth in international business [20].